Dr. Peter Frederick, MD
Claim this profileRoswell Park
Studies Endometrial Cancer
Studies Serous Cystadenocarcinoma
4 reported clinical trials
15 drugs studied
Area of expertise
1Endometrial Cancer
Stage III
Stage IV
2Serous Cystadenocarcinoma
Stage III
Stage IV
HER2 positive
Affiliated Hospitals
Clinical Trials Peter Frederick, MD is currently running
Targeted Therapy + Atezolizumab
for Endometrial Cancer
This trial tests drugs that target cancer cells, sometimes combined with an immune-boosting drug called atezolizumab. It focuses on patients with endometrial cancer that has returned or is persistent. The drugs are chosen based on the genetic profile of the patient's tumor to improve effectiveness.
Recruiting1 award Phase 1 & 25 criteria
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Recruiting1 award Phase 2 & 3
More about Peter Frederick, MD
Clinical Trial Related1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Peter Frederick, MD has experience with
- Carboplatin
- Paclitaxel
- Talazoparib
- Letrozole
- Inavolisib
- Atezolizumab
Breakdown of trials Peter Frederick, MD has run
Endometrial Cancer
Serous Cystadenocarcinoma
Endometrial Carcinoma
Endometrioid Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter Frederick, MD specialize in?
Peter Frederick, MD focuses on Endometrial Cancer and Serous Cystadenocarcinoma. In particular, much of their work with Endometrial Cancer has involved Stage III patients, or patients who are Stage IV.
Is Peter Frederick, MD currently recruiting for clinical trials?
Yes, Peter Frederick, MD is currently recruiting for 2 clinical trials in Buffalo New York. If you're interested in participating, you should apply.
Are there any treatments that Peter Frederick, MD has studied deeply?
Yes, Peter Frederick, MD has studied treatments such as Carboplatin, Paclitaxel, Talazoparib.
What is the best way to schedule an appointment with Peter Frederick, MD?
Apply for one of the trials that Peter Frederick, MD is conducting.
What is the office address of Peter Frederick, MD?
The office of Peter Frederick, MD is located at: Roswell Park, Buffalo, New York 14263 United States. This is the address for their practice at the Roswell Park.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.